Format

Send to

Choose Destination
Lancet Oncol. 2018 Dec;19(12):1561-1563. doi: 10.1016/S1470-2045(18)30654-5.

Pseudoprogression: fact or wishful thinking in neuro-oncology?

Author information

1
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5450, USA. Electronic address: david_reardon@dfci.harvard.edu.
2
Department of Neurology & Brain Tumor Center, University Hospital Zurich, CH-8091 Zurich, Switzerland.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center